ReutersRoche immunotherapy improves lung cancer survivalReutersA mid-stage trial of Roche Holding AG's experimental immunotherapy showed that it doubled the likelihood of survival for lung cancer patients with the highest levels of a specific biomarker. The drug, known by the code name MPDL3280A, is part of a new ...Roche drug shrinks tumors in half of patients with lung cancer mutationChannel News AsiaGenentech's Investigational Medicine Alectinib Shrank Tumors in Nearly Half of ...Digital JournalGenentech's Investigational Immunotherapy MPDL3280A Doubled the ...Yahoo Finance UKall 7 news articles »
